Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:ASXC NASDAQ:CLPT NASDAQ:NPCE NASDAQ:OM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASXCAsensus Surgical$0.35$0.35$0.17▼$0.40$94.74M1.372.03 million shsN/ACLPTClearPoint Neuro$11.38+0.4%$12.17$6.25▼$19.22$317.12M0.92261,213 shs351,732 shsNPCENeuroPace$9.08-0.3%$12.40$5.45▼$18.98$298.79M1.93187,213 shs191,406 shsOMOutset Medical$17.60-2.8%$19.25$5.85▼$68.18$320.77M2.15155,045 shs294,849 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASXCAsensus Surgical0.00%0.00%0.00%0.00%+3.67%CLPTClearPoint Neuro+1.61%-7.43%-2.33%-7.43%+49.28%NPCENeuroPace-2.57%-9.62%-17.85%-15.57%+13.59%OMOutset Medical+0.11%-11.79%-11.53%+64.40%-74.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASXCAsensus SurgicalN/AN/AN/AN/AN/AN/AN/AN/ACLPTClearPoint Neuro1.7044 of 5 stars3.51.00.00.01.90.80.6NPCENeuroPace3.5955 of 5 stars3.53.00.00.03.34.20.6OMOutset Medical1.4613 of 5 stars3.51.00.00.02.20.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASXCAsensus Surgical 0.00N/AN/AN/ACLPTClearPoint Neuro 3.00Buy$25.00119.68% UpsideNPCENeuroPace 3.00Buy$17.0087.22% UpsideOMOutset Medical 3.00Buy$29.5067.61% UpsideCurrent Analyst Ratings BreakdownLatest ASXC, OM, NPCE, and CLPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025OMOutset MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$37.005/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/21/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$14.00 ➝ $21.005/15/2025OMOutset MedicalScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.005/8/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $14.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASXCAsensus Surgical$8.58M11.04N/AN/A$0.13 per share2.68CLPTClearPoint Neuro$31.39M10.15N/AN/A$0.92 per share12.37NPCENeuroPace$79.91M3.73N/AN/A$0.27 per share33.63OMOutset Medical$113.69M2.74N/AN/A$7.49 per share2.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASXCAsensus Surgical-$78.43M-$0.31N/AN/AN/A-902.25%-184.10%-114.75%N/ACLPTClearPoint Neuro-$18.91M-$0.76N/AN/AN/A-64.51%-78.09%-51.33%8/6/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)OMOutset Medical-$127.98M-$29.15N/A∞N/A-98.74%-143.62%-37.50%8/6/2025 (Estimated)Latest ASXC, OM, NPCE, and CLPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NPCENeuroPace-$0.24N/AN/AN/A$23.08 millionN/A8/6/2025Q2 2025CLPTClearPoint Neuro-$0.20N/AN/AN/A$9.20 millionN/A8/6/2025Q2 2025OMOutset Medical-$1.76N/AN/AN/A$29.40 millionN/A5/13/2025Q1 2025CLPTClearPoint Neuro-$0.15-$0.22-$0.07-$0.22$8.21 million$8.49 million5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/7/2025Q1 2025OMOutset Medical-$0.97-$3.66-$2.69-$3.66$27.81 million$29.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASXCAsensus SurgicalN/AN/AN/AN/AN/ACLPTClearPoint NeuroN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASXCAsensus SurgicalN/A1.000.69CLPTClearPoint NeuroN/A3.532.57NPCENeuroPace2.466.635.70OMOutset Medical0.578.376.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASXCAsensus Surgical9.35%CLPTClearPoint Neuro30.08%NPCENeuroPace78.83%OMOutset MedicalN/AInsider OwnershipCompanyInsider OwnershipASXCAsensus Surgical2.87%CLPTClearPoint Neuro6.97%NPCENeuroPace20.50%OMOutset Medical2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASXCAsensus Surgical170272.33 million264.52 millionNot OptionableCLPTClearPoint Neuro11027.99 million26.04 millionOptionableNPCENeuroPace17032.80 million26.08 millionOptionableOMOutset Medical52017.72 million17.30 millionNot OptionableASXC, OM, NPCE, and CLPT HeadlinesRecent News About These CompaniesOutset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025July 16 at 4:03 PM | globenewswire.comWhy Outset Medical's Rock-Bottom Valuation Masks Explosive GrowthJuly 7, 2025 | seekingalpha.comOutset Medical (NASDAQ:OM) Shares Up 0.7% - Time to Buy?July 1, 2025 | marketbeat.comStrength Seen in Outset Medical (OM): Can Its 15.0% Jump Turn into More Strength?June 25, 2025 | zacks.comOutset Medical, Inc. (OM) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comOutset Medical to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 5, 2025 | globenewswire.comFormer Shockwave CFO joins Outset Medical in the same roleJune 4, 2025 | massdevice.comOutset Medical Appoints Renee Gaeta as Chief Financial OfficerJune 3, 2025 | globenewswire.comOutset Medical, Inc. (NASDAQ:OM) CFO Nabeel Ahmed Sells 584 SharesMay 17, 2025 | insidertrades.comOutset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of DirectorsMay 15, 2025 | uk.finance.yahoo.comOutset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of DirectorsMay 14, 2025 | globenewswire.comOutset Medical to Present at RBC Global Healthcare ConferenceMay 9, 2025 | globenewswire.comOutset Medical, Inc. (OM) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comOutset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comOutset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use DeclinedMay 7, 2025 | globenewswire.comOUTSET MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmApril 29, 2025 | globenewswire.comDoes Outset Medical (OM) Have the Potential to Rally 71.66% as Wall Street Analysts Expect?April 21, 2025 | zacks.comOutset Medical, Inc. Announces Q1 2025 Financial Results Release and Conference Call DetailsApril 16, 2025 | quiverquant.comQOutset Medical: The Worst Is Over, But Execution Risk Remains HighApril 16, 2025 | seekingalpha.comAnalysts Conflicted on These Healthcare Names: Outset Medical (OM) and AptarGroup (ATR)April 16, 2025 | markets.businessinsider.comPainful week for individual investors invested in Outset Medical, Inc. (NASDAQ:OM) after 18% drop, institutions also suffered lossesApril 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingASXC, OM, NPCE, and CLPT Company DescriptionsAsensus Surgical NYSEAMERICAN:ASXC$0.35 0.00 (0.00%) As of 08/22/2024Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.ClearPoint Neuro NASDAQ:CLPT$11.38 +0.05 (+0.44%) Closing price 04:00 PM EasternExtended Trading$11.58 +0.19 (+1.71%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.NeuroPace NASDAQ:NPCE$9.08 -0.03 (-0.33%) Closing price 04:00 PM EasternExtended Trading$9.08 0.00 (0.00%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Outset Medical NASDAQ:OM$17.60 -0.50 (-2.76%) Closing price 04:00 PM EasternExtended Trading$17.57 -0.04 (-0.20%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
